Home › Amyloidosis › California › San Francisco
Amyloidosis clinical trials in San Francisco, CA
4 studies for Amyloidosis are looking for participants at sites in and around San Francisco (within about 30 miles). Open a study to see who can join and how to contact the study team.
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
RecruitingPhase 1
- University of California San Francisco, San Francisco
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
RecruitingObservational study
- Research Site, San Francisco
- Research Site, San Francisco
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
RecruitingPhase 3
- University of California, San Francisco (UCSF), San Francisco
A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
RecruitingPhase 1/2
- Research Site, San Francisco
About Amyloidosis
Amyloidosis is a rare condition that can affect different organs of the body. Find out about amyloidosis treatment and symptoms.
More about Amyloidosis on MedlinePlus
Amyloidosis trials in other cities
- Boston, MA11 studies
- New York City, NY10 studies
- Rochester, MN10 studies
- Dallas, TX9 studies
- Philadelphia, PA7 studies
- Durham, NC6 studies
- St. Louis, MO6 studies
- Baltimore, MD6 studies
- Portland, OR6 studies
- Houston, TX6 studies
- Cleveland, OH5 studies
- Chicago, IL5 studies
Other studies in San Francisco
- Prostate Cancer45 studies
- Breast Cancer43 studies
- Non-Small Cell Lung Cancer37 studies
- Cancer (all types)35 studies
- Heart Failure29 studies
- Metastatic Cancer29 studies
- Lung Cancer23 studies
- Melanoma22 studies
- Pancreatic Cancer20 studies
- Colorectal Cancer19 studies
- Cardiovascular Disease18 studies
- Ovarian Cancer18 studies
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.